XML 29 R18.htm IDEA: XBRL DOCUMENT v3.26.3
Organization (Policies)
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying unaudited interim condensed financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 31, 2026 and as amended by Amendment No. 1 filed with the SEC on April 30, 2026 (collectively, the “2025 Annual Report”),

The results disclosed in the condensed statements of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the full fiscal year 2026.

Use of Estimates

Use of Estimates

The preparation of condensed financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

Nasdaq Stockholders' Equity Deficiency Notice

Nasdaq Stockholders' Equity Deficiency Notice

 

On April 9, 2026, the Company received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that the Company’s stockholders equity, as reported in its 2025 Annual Report, did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholder equity be at least $2.5 million. In its 2025 Annual Report Form 10-K, the Company reported stockholders’ equity of $2.2 million, and, as a result, did not satisfy Nasdaq Listing Rule 5550(b)(1) at that time.

 

Subsequent to September 30, 2026, the Company completed the PIPE on October 14, 2026, generating approximately $350.0 million in gross proceeds before placement agent fees and other offering expenses. In connection with the PIPE, Fairmount Healthcare Fund II, L.P. provided a limited waiver of cash-settlement rights covering 6,268 shares of Series C Preferred Stock, representing approximately $9.0 million. Before the PIPE, on October 5, 2026, the Company had received a written notice from the Listing Qualifications staff of Nasdaq informing the Company that its securities were subject to delisting due to its continued non-compliance with Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”) unless the Company timely requested a hearing before the Nasdaq Hearings Panel. The Company had timely submitted a plan to regain compliance and then timely requested a hearing, which was scheduled for November 10, 2026. On October 21, 2026, the Company disclosed its determination that the financing, including the effect of the waiver, had restored compliance with the Stockholders’ Equity Requirement.

 

On October 22, 2026, the Company received a letter from Nasdaq’s Office of General Counsel confirming that Nasdaq staff had determined that the Company had regained compliance with the Stockholders’ Equity Requirement. Nasdaq closed the matter and cancelled the November 10, 2026 hearing. The Company’s common stock continues to be listed and traded on the Nasdaq Capital Market.

 

Nasdaq will continue to monitor the Company’s compliance. If the Company does not evidence compliance when it files its Annual Report on Form 10-K for the year ending December 31, 2026, it may be subject to delisting. The September 30, 2026 balance sheet precedes the Asset Acquisition and the PIPE and therefore does not reflect their effects on stockholders’ equity. See Note 9. Subsequent

Events and Part II, Item 1A, “Risk Factors,” for additional information.

Nasdaq Minimum Market Value Requirement

Nasdaq Minimum Market Value Requirement

 

On July 22, 2026, the SEC’s Division of Trading and Markets, acting pursuant to delegated authority, approved a Nasdaq rule change that would require companies listed on the Nasdaq Capital Market to maintain a market value of listed securities (“MVLS”) of at least $5.0 million. Under the approved rule, a company whose MVLS remains below $5.0 million for 30 consecutive business days would be subject to an immediate staff delisting determination without an automatic compliance period. On July 29, 2026, following the filing of notices of intention to petition for review, the SEC automatically stayed the approval order pending further Commission action. As of the date these condensed financial statements were issued, the stay remained in effect. The Company cannot predict the timing or outcome of the SEC’s review, whether or when the rule will become operative, or the implementation and measurement procedures that may apply if the stay is lifted.